cphi-onlineAugust 11, 2017
Tag: Sanofi , Lantus , Merck Sharp & Dohme Corp. , patent infringement suit
Sanofi has filed a patent infringement suit to claim two patent rights against Merck Sharp & Dohme Corp. (on 8 August 2017) in the US District Court for the District of New Jersey.
The company claims rights of two patents.
The suit was triggered by a notification received from Merck in late June, in which Merck stated that it had filed an NDA (505(b)(2) New Drug Application) with FDA for an insulin glargine vial drug product.
Merck also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi's Lantus and Lantus SoloStar products.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: